NEWS RELEASE: Biogen-Idec will terminate its collaboration with Elan, the Dublin-based drug maker that developed Natalizumab, and buy Elan’s remaining 50% interest. Going forward, Biogen-Idec will control all marketing and distribution rights. In exchange, Biogen-Idec will make a $3.25 billion cash payment to Elan and will make future contingent payments to Elan equal to 12% of Natalizumab's global sales for the first year. After that, Biogen-Idec will make contingent payments of 18% on annual sales of Natalizumab up to $2 billion and 25% on annual sales that exceed $2 billion.
Read the whole article
"MS is clearly a lucrative field to be in as a pharma company. No wonder there is so much activity in the field."
"Are you surprised how well Natalizumab is doing despite the PML scare?"
Read the whole article
"MS is clearly a lucrative field to be in as a pharma company. No wonder there is so much activity in the field."
"Are you surprised how well Natalizumab is doing despite the PML scare?"
0 comments:
Post a Comment